MCID: MCR141
MIFTS: 51

Mucormycosis

Categories: Infectious diseases, Neuronal diseases, Oral diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Mucormycosis

MalaCards integrated aliases for Mucormycosis:

Name: Mucormycosis 12 74 52 58 3 15 17
Zygomycosis 12 74 52 58 3 32
Disseminated Mucormycosis 12 32

Characteristics:

Orphanet epidemiological data:

58
zygomycosis
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:8485
MESH via Orphanet 44 D009091 D020096
UMLS via Orphanet 72 C0026718 C0043541
Orphanet 58 ORPHA73263

Summaries for Mucormycosis

CDC : 3 Mucormycosis (sometimes called zygomycosis) is a serious but rare fungal infection caused by a group of molds called mucormycetes. These fungi live throughout the environment, particularly in soil and in decaying organic matter, such as leaves, compost piles, or rotten wood.1 People get mucormycosis by coming in contact with the fungal spores in the environment. For example, the lung or sinus forms of the infection can occur after someone breathes in spores. These forms of mucormycosis usually occur in people who have health problems or take medicines that lower the body's ability to fight germs and sickness.3,6 Mucormycosis can also develop on the skin after the fungus enters the skin through a cut, scrape, burn, or other type of skin trauma.

MalaCards based summary : Mucormycosis, also known as zygomycosis, is related to aspergillosis and fusariosis. An important gene associated with Mucormycosis is CSF3 (Colony Stimulating Factor 3), and among its related pathways/superpathways are MAPK signaling pathway and Hematopoietic cell lineage. The drugs Miconazole and Voriconazole have been mentioned in the context of this disorder. Affiliated tissues include sinuses, brain and lungs of immunocompromised people, and related phenotypes are hematopoietic system and digestive/alimentary

Disease Ontology : 12 An opportunistic mycosis that results in fungal infection located in sinuses, located in brain, or located in lungs of immunocompromised people, has material basis in Mucorales molds.

Wikipedia : 74 Mucormycosis is any fungal infection caused by fungi in the order Mucorales. Generally, species in the... more...

Related Diseases for Mucormycosis

Diseases related to Mucormycosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 609)
# Related Disease Score Top Affiliating Genes
1 aspergillosis 30.8 IFNG CSF3 CSF2 CLEC7A CCR6 CABIN1
2 fusariosis 30.6 CYP51A1 CSF3
3 pancytopenia 30.5 IFNG CSF3 CSF2 CD4
4 panophthalmitis 30.5 IFNG CD4
5 gastroenteritis 30.4 IFNG CSF3 CSF2
6 acquired immunodeficiency syndrome 30.4 IFNG CSF2 CD4 CCR6
7 cerebritis 30.3 RHNO1 CD4
8 candidiasis 30.2 IFNG CSF2 CLEC7A CARD9
9 aplastic anemia 30.2 IFNG CYP3A4 CSF3 CSF2 CD4
10 bacterial infectious disease 30.2 IFNG CSF3 CSF2 CD4 CCR6
11 chronic graft versus host disease 30.1 IFNG CD4
12 immune deficiency disease 30.1 IFNG CYP3A4 CSF2 CD4 CCR6
13 neuroretinitis 30.1 IFNG CD4
14 cryptococcosis 30.1 IFNG CSF2 CLEC7A CD4 CCR6
15 castleman disease 30.0 IFNG CSF3 CSF2
16 folliculitis 29.9 IFNG CD4 CCR6
17 lung abscess 29.9 IFNG FLNC CD4
18 diarrhea 29.9 PPIG IFNG CYP3A4 CSF3
19 histoplasmosis 29.9 IFNG CLEC7A CD4 CCR6
20 exanthem 29.9 CYP3A4 CSF3 CSF2 CD4 CCR6
21 human immunodeficiency virus type 1 29.9 IFNG HSPA5 CYP3A4 CD4
22 common cold 29.9 FLNC CSF2 CD4 CCR6
23 nocardiosis 29.9 CD4 CABIN1
24 bacterial pneumonia 29.9 CSF3 CD4 CCR6
25 temporal arteritis 29.9 IFNG CD4 CCR6
26 lymphadenitis 29.8 IFNG CD4 CCR6
27 ileus 29.8 INS IFNG CSF2
28 myeloma, multiple 29.8 IFNG HSPA5 CSF3 CSF2 CD4 CCR6
29 meningoencephalitis 29.7 CD4 CCR6 CARD9
30 acute cystitis 29.7 INS CD4 CCR6
31 nervous system disease 29.7 IFNG CSF2 CD4 CCR6
32 leprosy 3 29.7 IFNG CSF2 CD4 CCR6
33 otitis externa 29.7 RHNO1 B4GALNT2
34 pulmonary disease, chronic obstructive 29.5 PPIG INS CSF2 CD4 CCR6
35 chromoblastomycosis 29.5 CLEC7A CCR6 CARD9
36 paranasal sinus disease 29.4 RHNO1 IFNG FLNC CD4 CCR6
37 fungal meningitis 29.4 IFNG FLNC CYP51A1 CSF2 CD4
38 sporotrichosis 29.4 IFNG CLEC7A CD4 CARD9
39 phaeohyphomycosis 29.4 CLEC7A CARD9 B4GALNT2
40 conidiobolomycosis 29.3 PPIG CYP51A1 CYP3A4 B4GALNT2
41 peripheral nervous system disease 29.3 INS IFNG CSF3 CD4 CCR6
42 oral candidiasis 29.2 CLEC7A CD4 CCR6 CARD9
43 systemic lupus erythematosus 29.1 INS IFNG CYP2C19 CSF3 CSF2 CD4
44 pneumocystosis 29.1 FLNC CSF3 CLEC7A CD4 CCR6 CABIN1
45 invasive aspergillosis 29.1 IFNG FLNC CYP51A1 CYP2C19 CSF3 CLEC7A
46 subcutaneous mycosis 28.8 FLNC CLEC7A CCR6 CARD9 B4GALNT2
47 malaria 28.7 INS IFNG CYP3A4 CSF3 CSF2 CD4
48 coccidioidomycosis 28.7 CYP51A1 CLEC7A CD4 CCR6 CARD9
49 mycobacterium tuberculosis 1 28.4 PPIG IFNG CYP51A1 CYP3A4 CLEC7A CD4
50 opportunistic mycosis 27.6 RHNO1 IFNG FLNC CYP51A1 CSF3 CSF2

Graphical network of the top 20 diseases related to Mucormycosis:



Diseases related to Mucormycosis

Symptoms & Phenotypes for Mucormycosis

MGI Mouse Phenotypes related to Mucormycosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.9 B4GALNT2 CABIN1 CACNA1B CARD9 CCR6 CD4
2 digestive/alimentary MP:0005381 9.8 B4GALNT2 CD4 CLEC7A CYP51A1 HSPA5 IFNG
3 homeostasis/metabolism MP:0005376 9.77 B4GALNT2 CACNA1B CACNA1E CARD9 CCR6 CD4
4 immune system MP:0005387 9.4 B4GALNT2 CABIN1 CACNA1B CARD9 CCR6 CD4

Drugs & Therapeutics for Mucormycosis

Drugs for Mucormycosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 23)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
2
Voriconazole Approved Phase 4 137234-62-9 71616
3 Anti-Infective Agents Phase 4
4 Antifungal Agents Phase 4
5 Cytochrome P-450 CYP3A Inhibitors Phase 4
6 Cytochrome P-450 Enzyme Inhibitors Phase 4
7 Hormone Antagonists Phase 4
8 Steroid Synthesis Inhibitors Phase 4
9 Hormones Phase 4
10
Isavuconazole Approved, Investigational Phase 3 241479-67-4
11
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381
12
Amphotericin B Approved, Investigational Phase 2 1397-89-3 14956 5280965
13
Iron Approved, Experimental Phase 2 7439-89-6, 15438-31-0 23925 27284
14
Posaconazole Approved, Investigational, Vet_approved Phase 2 171228-49-2 147912
15 Anti-Bacterial Agents Phase 2
16 Antiparasitic Agents Phase 2
17 Antiprotozoal Agents Phase 2
18 Chelating Agents Phase 2
19 Liposomal amphotericin B Phase 2
20 Iron Chelating Agents Phase 2
21 Nutrients Phase 2
22 Trace Elements Phase 2
23 Micronutrients Phase 2

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 A Prospective, Randomized Trial Comparing the Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing Completed NCT01416025 Phase 4 Prospective TDM Arm
2 A Phase 3, Multi-center, Open Label Study to Evaluate Safety and Efficacy of AK1820 for Treatment of Adult Japanese Patients With Deep Mycosis Recruiting NCT03471988 Phase 3 AK1820;Voriconazole
3 Treatment of Rhino-Sinusal Mucormycosis Through Transnasal Endoscopic Surgery Extended to the Skull Base. Unknown status NCT02226705 Phase 2
4 The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study Completed NCT00419770 Phase 2 deferasirox;Placebo;Liposomal amphotericin B
5 AMBIZYGO: Efficacy of High Dose [10 mg/kg/j] Liposomal Amphotericin B (Ambisome)Efficacy in Initial Zygomycosis Treatment:Phase II Trial Completed NCT00467883 Phase 2 Liposomal Amphotericin B
6 Phase II Study of Safety, Tolerance, Efficacy, and Pharmacokinetics of Posaconazole (SCH 56592) for the Treatment of Invasive Fungal Infections in Immunocompromised Hosts Completed NCT00034671 Phase 2 Posaconazole oral suspension
7 A Phase II Trial of the Safety and Efficacy of Iron Reduction by Phlebotomy in Recipients of Hematopoietic Stem Cell Transplants Completed NCT00689182 Phase 2
8 A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects Recruiting NCT03816176 Phase 2 Isavuconazonium sulfate;Isavuconazonium sulfate
9 Mucormycosis in ICU: A French Multicenter Cohort Study Unknown status NCT03387696
10 Systemic Fungal Infections in Intensive Care Unit Patients Unknown status NCT03292224
11 The Value of Real-Time Polymerase Chain Reaction (RT-PCR) Assay, Galactomannan and β-D-Glucan Detection (GM/G-Test) for Diagnosis of Invasive Fungal Infection (IFI) in Chinese Patients After Hematopoietic Stem Cell Transplantation (HSCT) Unknown status NCT00460330
12 Prospective Evaluation of a New Molecular Tool for Early Diagnosis of Mucormycosis Completed NCT02845934
13 Multicenter Observational Study on Epidemiology, Treatment and Outcome of Mucormycosis in India Completed NCT03429023
14 Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis Completed NCT00923832
15 Invasive Mould Infections in Indian ICUs - Descriptive Epidemiology, Management and Outcome Completed NCT02683642

Search NIH Clinical Center for Mucormycosis

Genetic Tests for Mucormycosis

Anatomical Context for Mucormycosis

The Foundational Model of Anatomy Ontology organs/tissues related to Mucormycosis:

19
Sinuses, Brain, Lungs Of Immunocompromised People

MalaCards organs/tissues related to Mucormycosis:

40
Lung, Bone, Liver, Kidney, Skin, Brain, Myeloid

Publications for Mucormycosis

Articles related to Mucormycosis:

(show top 50) (show all 4128)
# Title Authors PMID Year
1
Multi-fungal sepsis and mucormycosis of the central nervous system in a patient treated with ibrutinib, a case report and review of the literature. 61
31890489 2020
2
Complication of massive trauma by fungal infection and bone tuberculosis. 61
31890488 2020
3
Positive quantitative PCR detecting Fusarium solani in a case of mixed invasive fungal disease due to Mucorales and Fusarium solani. 61
32024993 2020
4
High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections. 61
31660650 2020
5
A population-based analysis of attributable hospitalisation costs of invasive fungal diseases in haematological malignancy patients using data linkage of state-wide registry and costing databases: 2009-2015. 61
31715052 2020
6
Surgical resection for persistent localized pulmonary fungal infection prior to allogeneic hematopoietic stem cell transplantation: Analysis of six cases. 61
31735628 2020
7
Mucormycosis. 61
32000287 2020
8
Rhino-orbito-cerebral Mucormycosis in Diabetic Disease. 61
32028364 2020
9
Orbital apex syndrome caused by Alternaria species: A novel invasive fungus and new treatment paradigm. 61
30822175 2020
10
A comparison of histomorphologic diagnosis with culture- and immunohistochemistry-based diagnosis of invasive aspergillosis and mucormycosis. 61
31973617 2020
11
A Radical Approach to Acute Lymphoblastic Leukemia Treatment: A Case Study of a Veterinarian Specializing in Livestock who Developed Disseminated Mucormycosis during Induction Therapy. 61
31941872 2020
12
Invasive mucormycosis in a renal transplant recipient. 61
31901346 2020
13
Gastrointestinal Mucormycosis Presenting as Emphysematous Gastritis After Stem Cell Transplant for Myeloma. 61
31902426 2020
14
Pulmonary Mucormycosis: A Case Report of a Rare Infection with Potential Diagnostic Problems. 61
31970007 2020
15
CT Halo sign: A systematic review. 61
32007819 2020
16
Paediatric mucormycosis: tailoring surgical strategies to compliment antifungal chemotherapy. Different strokes for different folks. 61
31928201 2020
17
Treatment of localized mucormycosis using nasal amphotericin B irrigation in pediatric oncology. 61
31925929 2020
18
Pulmonary mucormycosis with diaphragm and liver involvement in a patient with haematopoietic stem cell transplant. 61
31549146 2020
19
Corrigendum to "Gastrointestinal mucormycosis post lung transplantation" [Braz J Infect Dis 23 (2019) 368-370]. 61
31904349 2020
20
Mucormycosis-induced ileocecal perforation: A case report and review of literature. 61
31929312 2020
21
The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom. 61
31262225 2020
22
A Novel Resistance Pathway for Calcineurin Inhibitors in the Human-Pathogenic Mucorales Mucor circinelloides. 61
31992620 2020
23
An aero mycological analysis of Mucormycetes in indoor and outdoor environments of northern India. 61
30980083 2020
24
Microsatellite analysis of the population structure in Rhizopus arrhizus. 61
31965685 2020
25
Mucormycosis with peculiar aortic involvement in a child with acute lymphoblastic leukemia. 61
31847684 2019
26
Clinical spectrum and outcome of hospitalized patients with invasive fungal infections: a prospective study from a medical ward/intensive care unit of a teaching hospital in North India. 61
31846989 2019
27
A Retrospective Analysis of Invasive Fungal Diseases (IFD) of the Central Nervous System in Children With Lymphoid Malignancies. 61
31815886 2019
28
Use of Antifungals and Outcomes Among Inpatients at Risk of Invasive Aspergillosis or Mucormycosis in the USA: A Retrospective Cohort Study. 61
31598932 2019
29
Orbital mycoses in an adult subtropical population. 61
31822858 2019
30
Quantifying guideline adherence in mucormycosis management using the EQUAL score. 61
31876327 2019
31
Amphotericin-induced pancytopenia in a patient with rhino-orbital mucormycosis. 61
31879335 2019
32
Disseminated Gastrointestinal Basidiobolomycosis (GIB) in an infant from Western India. 61
31667059 2019
33
Combination of amphotericin B and caspofungin in the treatment of mucormycosis. 61
31667058 2019
34
Mucormycosis in children with haematological malignancies is a salvageable disease: a report from the Israeli Study Group of Childhood Leukemia. 61
31885080 2019
35
Special Issue: Mucorales and Mucormycosis. 61
31877973 2019
36
The reversed halo sign and mucormycosis. 61
31782402 2019
37
Serial Detection of Circulating Mucorales DNA in Invasive Mucormycosis: A Retrospective Multicenter Evaluation. 61
31816976 2019
38
Mucormycosis in a patient with acute myeloblastic leukemia following liver transplantation for Wilson's disease. 61
31885243 2019
39
Gastrointestinal bleeding due to duodenal mucormycosis in an immunocompetent host mimicking malignancy. 61
31617363 2019
40
Clinical features of pulmonary mucormycosis in patients with different immune status. 61
32030220 2019
41
A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. 61
31811914 2019
42
Mucormycosis in lung transplant recipients: A systematic review of the literature and a case series. 61
31860739 2019
43
Gastrointestinal Mucormycosis in a two-year-old child: A clinical and radiological enigma. 61
31667050 2019
44
Cutaneous mucormycosis by Rhizopus arrhizus treated with isavuconazole as first line therapy: A case report. 61
31667060 2019
45
Mucormycosis: an unusual masquerader of an endobronchial tumour. 61
31576206 2019
46
From the Pharynx to the Brain: A Case of Rapidly Progressing Mucormycosis. 61
31655951 2019
47
Surgical-site mucormycosis infection in a solid-organ transplant recipient and a concise review of the literature. 61
31826901 2019
48
Pulmonary mucormycosis in a patient with acute liver failure: A case report and systematic review of the literature. 61
31881411 2019
49
Control of an outbreak of post-transplant cutaneous mucormycosis by removing the vehicle: An intervention study of contiguous cohorts. 61
31812269 2019
50
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. 61
31699664 2019

Variations for Mucormycosis

Expression for Mucormycosis

Search GEO for disease gene expression data for Mucormycosis.

Pathways for Mucormycosis

GO Terms for Mucormycosis

Cellular components related to Mucormycosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 organelle membrane GO:0031090 9.13 CYP51A1 CYP3A4 CYP2C19
2 intracellular membrane-bounded organelle GO:0043231 9.1 HSPA5 CYP51A1 CYP3A4 CYP2C19 CSF2 CLEC7A

Biological processes related to Mucormycosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.85 INS IFNG CSF3 CSF2 CLEC7A
2 immune response GO:0006955 9.83 IFNG CSF3 CSF2 CD4 CCR6
3 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.48 CLEC7A CD4
4 negative regulation of amyloid-beta clearance GO:1900222 9.4 IFNG CYP51A1
5 cellular response to granulocyte macrophage colony-stimulating factor stimulus GO:0097011 9.37 CSF2 CD4
6 positive regulation of respiratory burst GO:0060267 9.32 INS CLEC7A
7 heterocycle metabolic process GO:0046483 9.26 CYP3A4 CYP2C19
8 positive regulation of killing of cells of other organism GO:0051712 9.16 IFNG CLEC7A
9 monoterpenoid metabolic process GO:0016098 8.96 CYP3A4 CYP2C19
10 positive regulation of interleukin-23 production GO:0032747 8.62 IFNG CSF2

Molecular functions related to Mucormycosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.13 CYP51A1 CYP3A4 CYP2C19
2 enzyme binding GO:0019899 9.02 HSPA5 CYP3A4 CYP2C19 CSF3 CD4

Sources for Mucormycosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....